苯那普利延缓糖尿病肾病进展的疗效研究

为观察血管紧张素转换酶抑制剂 (ACEI)苯那普利对改善糖尿病肾病 (DN)患者肾脏病变的疗效 ,选择 1998年 1月至 1999年 12月 5 4例 型糖尿病伴肾脏病变患者 ,随机分为 A、B两组 ,均坚持饮食控制和降糖治疗 ,停服 ACEI两周后 ,A组给予苯那普利 10 mg/d晨间口服 6个月 ,B组不服 ACEI。检测两组实验初及 6个月时空腹血糖 (FBG)、血尿素 (BU N)、血肌酐 (Scr)、糖化血红蛋白 (Hb A1c)、尿白蛋白排泄量 (UAE)、血清 型胶原 (C )和层粘蛋白(L N)并比较。结果表明 ,苯那普利治疗后 U AE、C 、L N均较治疗前以及未予治疗组明显降低 ,UAE减少与 C 、L N水平降低呈显著正相关关系。说明苯那普利对治疗 DN、延缓肾病进展及改善肾功能有较好疗效

Effect of Benazepril on the Progression of Diabetic Nephropathy

To investigate the effect of Benazepril on the progression of diabetic nephropathy (DN), 54 patients with diabetic nephropathy from Jan. 1998 to Dec. 1999 were randomly divided into groups A and B. Both groups A and B accepted the medicines controlling blood glucose, but Benazepril (10 mg/d) was additionally administered to group A for 6 months. The levels of serum FBG, BUN, Scr, HbA1c, UAE, CIV and LN in the two groups were determined before and after treatment, respectively. The results showed that after treatment of Benazepril for 6 months, the levels of UAE, CIV and LN in group A were significantly increased as compared with those before treatment and those without given Benazepril. The decrease of UAE was positively related with the decreases of CIV and LN. It was suggested that Benazepril had better therapeutic effects in treating DN, delaying the progression of DN and improving renal function.